(4) equipment utilized in the mw drug substance manufacturing process is deficient.
Inspection Record
WuXi Biologics Ireland Limited — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Laboratory controls are inadequate to ensure reliable analytical testing of critical quality and safety attributes.
Laboratory investigation procedures for Out of Specification (OOS) results are inadequate.
A record as of the US FDA document published on 2026-10-22. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.